Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA)

Progress in Neurobiology

Volumn 99, Issue 3, 2012, Pages 246-256

  Katsuno, Masahisa ^a   Tanaka, Fumiaki ^a   Adachi, Hiroaki ^a   Banno, Haruhiko ^a,b   Suzuki, Keisuke ^a   Watanabe, Hirohisa ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Androgen receptor; Animal model; Autophagy; Clinical trial; Luteinizing hormone releasing hormone analog; Molecular chaperone; Motor neuron; Neurodegeneration; Polyglutamine; Spinal and bulbar muscular atrophy; Ubiquitin proteasome

Indexed keywords

5 HYDROXY 1,7 BIS(3,4 DIMETHOXYPHENYL) 1,4,6 HEPTATRIEN 3 ONE; ALVESPIMYCIN; ANDROGEN RECEPTOR; BUTYRIC ACID; CHAPERONE; DUTASTERIDE; LEUPRORELIN; POLYGLUTAMINE; PROTEASOME; RAPAMYCIN; UBIQUITIN; UNCLASSIFIED DRUG;

BULBAR MUSCULAR ATROPHY; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA BINDING; ENDOMETRIOSIS; GENDER; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MOTOR NEURON DISEASE; MUSCLE ATROPHY; MYOPATHY; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SPINAL MUSCULAR ATROPHY; TRANSCRIPTION REGULATION;

ANIMALS; HUMANS; MUSCULAR ATROPHY, SPINAL; MUSCULAR DISORDERS, ATROPHIC; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEATS;

EID: 84869870525     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.05.007     Document Type: Review

References (137)

1. Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Do J., Sang C., Kobayashi Y., Doyu M., Sobue G. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Human Molecular Genetics 2001, 10:1039-1048.
2. Adachi H., Katsuno M., Minamiyama M., Sang C., Pagoulatos G., Angelidis C., Kusakabe M., Yoshiki A., Kobayashi Y., Doyu M., Sobue G. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. Journal of Neuroscience 2003, 23:2203-2211.
3. Adachi H., Katsuno M., Minamiyama M., Waza M., Sang C., Nakagomi Y., Kobayashi Y., Tanaka F., Doyu M., Inukai A., Yoshida M., Hashizume Y., Sobue G. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005, 128:659-670.
4. Adachi H., Waza M., Tokui K., Katsuno M., Minamiyama M., Tanaka F., Doyu M., Sobue G. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. Journal of Neuroscience 2007, 27:5115-5126.
5. Andrew S.E., Goldberg Y.P., Hayden M.R. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. Human Molecular Genetics 1997, 6:2005-2010.
6. Atsuta N., Watanabe H., Ito M., Banno H., Suzuki K., Katsuno M., Tanaka F., Tamakoshi A., Sobue G. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006, 129:1446-1455.
7. Bailey C.K., Andriola I.F., Kampinga H.H., Merry D.E. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Human Molecular Genetics 2002, 11:515-523.
8. Banno H., Adachi H., Katsuno M., Suzuki K., Atsuta N., Watanabe H., Tanaka F., Doyu M., Sobue G. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Annals of Neurology 2006, 59:520-526.
9. Banno H., Katsuno M., Suzuki K., Takeuchi Y., Kawashima M., Suga N., Takamori M., Ito M., Nakamura T., Matsuo K., Yamada S., Oki Y., Adachi H., Minamiyama M., Waza M., Atsuta N., Watanabe H., Fujimoto Y., Nakashima T., Tanaka F., Doyu M., Sobue G. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Annals of Neurology 2009, 65:140-150.
10. Battaglia F., Le Galudec V., Cossee M., Tranchant C., Warter J.M., Echaniz-Laguna A. Kennedy's disease initially manifesting as an endocrine disorder. Journal of Clinical Neuromuscular Disease 2003, 4:165-167.
11. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. Journal of Neurochemistry 2009, 110:1737-1765.
12. Brinkmann A.O. Lessons to be learned from the androgen receptor. European Journal of Dermatology 2001, 11:301-303.
13. Butler R., Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nature Reviews Neuroscience 2006, 7:784-796.
14. Chahin N., Sorenson E.J. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle and Nerve 2009, 40:126-129.
15. Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H.J., Wang C., Mizokami A. Androgen receptor: an overview. Critical Reviews in Eukaryotic Gene Expression 1995, 5:97-125.
16. Chevalier-Larsen E.S., O'Brien C.J., Wang H., Jenkins S.C., Holder L., Lieberman A.P., Merry D.E. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. Journal of Neuroscience 2004, 24:4778-4786.
17. Clark P.E., Irvine R.A., Coetzee G.A. The androgen receptor CAG repeat and prostate cancer risk. Methods in Molecular Medicine 2003, 81:255-266.
18. Custer S.K., Garden G.A., Gill N., Rueb U., Libby R.T., Schultz C., Guyenet S.J., Deller T., Westrum L.E., Sopher B.L., La Spada A.R. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nature Neuroscience 2006, 9:1302-1311.
19. Davis-Dao C., Koh C.J., Hardy B.E., Chang A., Kim S.S., De Filippo R., Hwang A., Pike M.C., Carroll J.D., Coetzee G.A., Vandenberg D., Siegmund K., Cortessis V.K. Shorter androgen receptor CAG repeat lengths associated with cryptorchidism risk among Hispanic white boys. Journal of Clinical Endocrinology and Metabolism 2012, 97:E393-E399.
20. Dejager S., Bry-Gauillard H., Bruckert E., Eymard B., Salachas F., LeGuern E., Tardieu S., Chadarevian R., Giral P., Turpin G. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. Journal of Clinical Endocrinology and Metabolism 2002, 87:3893-3901.
21. Doyu M., Sobue G., Mukai E., Kachi T., Yasuda T., Mitsuma T., Takahashi A. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Annals of Neurology 1992, 32:707-710.
22. Fernandez-Rhodes L.E., Kokkinis A.D., White M.J., Watts C.A., Auh S., Jeffries N.O., Shrader J.A., Lehky T.J., Li L., Ryder J.E., Levy E.W., Solomon B.I., Harris-Love M.O., La Pean A., Schindler A.B., Chen C., Di Prospero N.A., Fischbeck K.H. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. The Lancet Neurology 2011, 10:140-147.
23. Finsterer J. Perspectives of Kennedy's disease. Journal of the Neurological Sciences 2010, 298:1-10.
24. Fischbeck K.H. Kennedy disease. Journal of Inherited Metabolic Disease 1997, 20:152-158.
25. Fischbeck K.H., Ionasescu V., Ritter A.W., Ionasescu R., Davies K., Ball S., Bosch P., Burns T., Hausmanowa-Petrusewicz I., Borkowska J., et al. Localization of the gene for X-linked spinal muscular atrophy. Neurology 1986, 36:1595-1598.
26. Gelmann E.P. Molecular biology of the androgen receptor. Journal of Clinical Oncology 2002, 20:3001-3015.
27. Guidetti D., Vescovini E., Motti L., Ghidoni E., Gemignani F., Marbini A., Patrosso M.C., Ferlini A., Solime F. X-linked bulbar and spinal muscular atrophy, or Kennedy disease: clinical, neurophysiological, neuropathological, neuropsychological and molecular study of a large family. Journal of the Neurological Sciences 1996, 135:140-148.
28. Guidetti D., Sabadini R., Ferlini A., Torrente I. Epidemiological survey of X-linked bulbar and spinal muscular atrophy, or Kennedy disease, in the province of Reggio Emilia, Italy. European Journal of Epidemiology 2001, 17:587-591.
29. Hafezparast M., Klocke R., Ruhrberg C., Marquardt A., Ahmad-Annuar A., Bowen S., Lalli G., Witherden A.S., Hummerich H., Nicholson S., Morgan P.J., Oozageer R., Priestley J.V., Averill S., King V.R., Ball S., Peters J., Toda T., Yamamoto A., Hiraoka Y., Augustin M., Korthaus D., Wattler S., Wabnitz P., Dickneite C., Lampel S., Boehme F., Peraus G., Popp A., Rudelius M., Schlegel J., Fuchs H., Hrabe de Angelis M., Schiavo G., Shima D.T., Russ A.P., Stumm G., Martin J.E., Fisher E.M. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003, 300:808-812.
30. Hama T., Hirayama M., Hara T., Nakamura T., Atsuta N., Banno H., Suzuki K., Katsuno M., Tanaka F., Sobue G. Discrimination of spinal and bulbar muscular atrophy from amyotrophic lateral sclerosis using sensory nerve action potentials. Muscle and Nerve 2012, 45:169-174.
31. Hanajima R., Terao Y., Nakatani-Enomoto S., Hamada M., Yugeta A., Matsumoto H., Yamamoto T., Tsuji S., Ugawa Y. Postural tremor in X-linked spinal and bulbar muscular atrophy. Movement Disorders 2009, 24:2063-2069.
32. Harding A.E., Thomas P.K., Baraitser M., Bradbury P.G., Morgan-Hughes J.A., Ponsford J.R. X-linked recessive bulbospinal neuronopathy: a report of ten cases. Journal of Neurology, Neurosurgery and Psychiatry 1982, 45:1012-1019.
33. Hay D.G., Sathasivam K., Tobaben S., Stahl B., Marber M., Mestril R., Mahal A., Smith D.L., Woodman B., Bates G.P. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Human Molecular Genetics 2004, 13:1389-1405.
34. Heinlein C.A., Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Molecular Endocrinology 2002, 16:2181-2187.
35. Higashihara M., Sonoo M., Yamamoto T., Nagashima Y., Uesugi H., Terao Y., Ugawa Y., Stalberg E., Tsuji S. Evaluation of spinal and bulbar muscular atrophy by the clustering index method. Muscle and Nerve 2011, 44:539-546.
36. Igarashi S., Tanno Y., Onodera O., Yamazaki M., Sato S., Ishikawa A., Miyatani N., Nagashima M., Ishikawa Y., Sahashi K., et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology 1992, 42:2300-2302.
37. Inoue K., Hemmi S., Miyaishi M., Kutoku Y., Murakami T., Kurokawa K., Sunada Y. Muscular fatigue and decremental response to repetitive nerve stimulation in X-linked spinobulbar muscular atrophy. European Journal of Neurology 2009, 16:76-80.
38. Ishihara H., Kanda F., Nishio H., Sumino K., Chihara K. Clinical features and skewed X-chromosome inactivation in female carriers of X-linked recessive spinal and bulbar muscular atrophy. Journal of Neurology 2001, 248:856-860.
39. Jenster G., van der Korput H.A., Trapman J., Brinkmann A.O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. Journal of Biological Chemistry 1995, 270:7341-7346.
40. Jochum T., Ritz M.E., Schuster C., Funderburk S.F., Jehle K., Schmitz K., Brinkmann F., Hirtz M., Moss D., Cato A.C. Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochimica et Biophysica Acta 2012, 1822:1070-1078.
41. Johansen J.A., Yu Z., Mo K., Monks D.A., Lieberman A.P., Breedlove S.M., Jordan C.L. Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy. Neurobiology of Disease 2009, 34:113-120.
42. Kachi T., Sobue G., Sobue I. Central motor and sensory conduction in X-linked recessive bulbospinal neuronopathy. Journal of Neurology, Neurosurgery and Psychiatry 1992, 55:394-397.
43. Karitzky J., Block W., Mellies J.K., Traber F., Sperfeld A., Schild H.H., Haller P., Ludolph A.C. Proton magnetic resonance spectroscopy in Kennedy syndrome. Archives of Neurology 1999, 56:1465-1471.
44. Kassubek J., Juengling F.D., Sperfeld A.D. Widespread white matter changes in Kennedy disease: a voxel based morphometry study. Journal of Neurology, Neurosurgery and Psychiatry 2007, 78:1209-1212.
45. Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002, 35:843-854.
46. Katsuno M., Adachi H., Doyu M., Minamiyama M., Sang C., Kobayashi Y., Inukai A., Sobue G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature Medicine 2003, 9:768-773.
47. Katsuno M., Sang C., Adachi H., Minamiyama M., Waza M., Tanaka F., Doyu M., Sobue G. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:16801-16806.
48. Katsuno M., Adachi H., Waza M., Banno H., Suzuki K., Tanaka F., Doyu M., Sobue G. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Experimental Neurology 2006, 200:8-18.
49. Katsuno M., Adachi H., Minamiyama M., Waza M., Tokui K., Banno H., Suzuki K., Onoda Y., Tanaka F., Doyu M., Sobue G. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. Journal of Neuroscience 2006, 26:12106-12117.
50. Katsuno M., Adachi H., Minamiyama M., Waza M., Doi H., Kondo N., Mizoguchi H., Nitta A., Yamada K., Banno H., Suzuki K., Tanaka F., Sobue G. Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. Journal of Neuroscience 2010, 30:5702-5712.
51. Katsuno M., Banno H., Suzuki K., Takeuchi Y., Kawashima M., Yabe I., Sasaki H., Aoki M., Morita M., Nakano I., Kanai K., Ito S., Ishikawa K., Mizusawa H., Yamamoto T., Tsuji S., Hasegawa K., Shimohata T., Nishizawa M., Miyajima H., Kanda F., Watanabe Y., Nakashima K., Tsujino A., Yamashita T., Uchino M., Fujimoto Y., Tanaka F., Sobue G. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2010, 9:875-884.
52. Kawahara H. A family of progressive bulbar palsy. Aichi Medical School Journal 1897, 16:3-4.
53. Kemp M.Q., Poort J.L., Baqri R.M., Lieberman A.P., Breedlove S.M., Miller K.E., Jordan C.L. Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action. Human Molecular Genetics 2011, 20:4475-4490.
54. Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968, 18:671-680.
55. Kinirons P., Rouleau G.A. Administration of testosterone results in reversible deterioration in Kennedy's disease. Journal of Neurology, Neurosurgery and Psychiatry 2008, 79:106-107.
56. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53.
57. Kobayashi Y., Kume A., Li M., Doyu M., Hata M., Ohtsuka K., Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. Journal of Biological Chemistry 2000, 275:8772-8778.
58. LaFevre-Bernt M.A., Ellerby L.M. Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. Journal of Biological Chemistry 2003, 278:34918-34924.
59. La Spada A.R., Taylor J.P. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nature Reviews Genetics 2010, 11:247-258.
60. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
61. Lehky T.J., Chen C.J., di Prospero N.A., Rhodes L.E., Fischbeck K., Floeter M.K. Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy. Muscle and Nerve 2009, 40:809-814.
62. Li M., Chevalier-Larsen E.S., Merry D.E., Diamond M.I. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. Journal of Biological Chemistry 2007, 282:3157-3164.
63. Li M., Miwa S., Kobayashi Y., Merry D.E., Yamamoto M., Tanaka F., Doyu M., Hashizume Y., Fischbeck K.H., Sobue G. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Annals of Neurology 1998, 44:249-254.
64. Li M., Nakagomi Y., Kobayashi Y., Merry D.E., Tanaka F., Doyu M., Mitsuma T., Hashizume Y., Fischbeck K.H., Sobue G. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. American Journal of Pathology 1998, 153:695-701.
65. Li M., Sobue G., Doyu M., Mukai E., Hashizume Y., Mitsuma T. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression. Muscle and Nerve 1995, 18:301-308.
66. Lund A., Udd B., Juvonen V., Andersen P.M., Cederquist K., Davis M., Gellera C., Kolmel C., Ronnevi L.O., Sperfeld A.D., Sorensen S.A., Tranebjaerg L., Van Maldergem L., Watanabe M., Weber M., Yeung L., Savontaus M.L. Multiple founder effects in spinal and bulbar muscular atrophy (SBMA, Kennedy disease) around the world. European Journal of Human Genetics 2001, 9:431-436.
67. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Human Molecular Genetics 2000, 9:1259-1271.
68. Malik B., Nirmalananthan N., Bilsland L.G., La Spada A.R., Hanna M.G., Schiavo G., Gallo J.M., Greensmith L. Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. Human Molecular Genetics 2011, 20:1776-1786.
69. Meriggioli M.N., Rowin J. Fatigue and abnormal neuromuscular transmission in Kennedy's disease. Muscle and Nerve 2003, 27:249-251.
70. Miller J., Arrasate M., Brooks E., Libeu C.P., Legleiter J., Hatters D., Curtis J., Cheung K., Krishnan P., Mitra S., Widjaja K., Shaby B.A., Lotz G.P., Newhouse Y., Mitchell E.J., Osmand A., Gray M., Thulasiramin V., Saudou F., Segal M., Yang X.W., Masliah E., Thompson L.M., Muchowski P.J., Weisgraber K.H., Finkbeiner S. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nature Chemical Biology 2011, 7:925-934.
71. Minamiyama M., Katsuno M., Adachi H., Waza M., Sang C., Kobayashi Y., Tanaka F., Doyu M., Inukai A., Sobue G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics 2004, 13:1183-1192.
72. Mirowska-Guzel D., Seniow J., Sulek A., Lesniak M., Czlonkowska A. Are cognitive and behavioural deficits a part of the clinical picture in Kennedy's disease? A case study. Neurocase 2009, 15:332-337.
73. Mo K., Razak Z., Rao P., Yu Z., Adachi H., Katsuno M., Sobue G., Lieberman A.P., Westwood J.T., Monks D.A. Microarray analysis of gene expression by skeletal muscle of three mouse models of kennedy disease/spinal bulbar muscular atrophy. PLoS One 2010, 5:e12922.
74. Monks D.A., Johansen J.A., Mo K., Rao P., Eagleson B., Yu Z., Lieberman A.P., Breedlove S.M., Jordan C.L. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:18259-18264.
75. Montie H.L., Cho M.S., Holder L., Liu Y., Tsvetkov A.S., Finkbeiner S., Merry D.E. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics 2009, 18:1937-1950.
76. Montie H.L., Pestell R.G., Merry D.E. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. Journal of Neuroscience 2011, 31:17425-17436.
77. Morfini G., Pigino G., Szebenyi G., You Y., Pollema S., Brady S.T. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nature Neuroscience 2006, 9:907-916.
78. Muchowski P.J., Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nature Reviews Neuroscience 2005, 6:11-22.
79. Mukherjee S., Thomas M., Dadgar N., Lieberman A.P., Iniguez-Lluhi J.A. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. Journal of Biological Chemistry 2009, 284:21296-21306.
80. Nagai Y., Inui T., Popiel H.A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H., Toda T. A toxic monomeric conformer of the polyglutamine protein. Nature Structural & Molecular Biology 2007, 14:332-340.
81. Nagai Y., Fujikake N., Popiel H.A., Wada K. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Current Pharmaceutical Biotechnology 2010, 11:188-197.
82. Nagashima T., Seko K., Hirose K., Mannen T., Yoshimura S., Arima R., Nagashima K., Morimatsu Y. Familial bulbo-spinal muscular atrophy associated with testicular atrophy and sensory neuropathy (Kennedy-Alter-Sung syndrome). Autopsy case report of two brothers. Journal of the Neurological Sciences 1988, 87:141-152.
83. Nedelsky N.B., Pennuto M., Smith R.B., Palazzolo I., Moore J., Nie Z., Neale G., Taylor J.P. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010, 67:936-952.
84. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
85. Orr C.R., Montie H.L., Liu Y., Bolzoni E., Jenkins S.C., Wilson E.M., Joseph J.D., McDonnell D.P., Merry D.E. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. Journal of Biological Chemistry 2010, 285:35567-35577.
86. Orr C.R., Montie H.L., Liu Y., Bolzoni E., Jenkins S.C., Wilson E.M., Joseph J.D., McDonnell D.P., Merry D.E. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. Journal of Biological Chemistry 2011, 285:35567-35577.
87. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annual Review of Neuroscience 2007, 30:575-621.
88. Pachatz C., Terracciano C., Desiato M.T., Orlacchio A., Mori F., Rocchi C., Bernardi G., Massa R. Upper motor neuron involvement in X-linked recessive bulbospinal muscular atrophy. Clinical Neurophysiology 2007, 118:262-268.
89. Palazzolo I., Burnett B.G., Young J.E., Brenne P.L., La Spada A.R., Fischbeck K.H., Howell B.W., Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Human Molecular Genetics 2007, 16:1593-1603.
90. Palazzolo I., Gliozzi A., Rusmini P., Sau D., Crippa V., Simonini F., Onesto E., Bolzoni E., Poletti A. The role of the polyglutamine tract in androgen receptor. Journal of Steroid Biochemistry and Molecular Biology 2008, 108:245-253.
91. Palazzolo I., Stack C., Kong L., Musaro A., Adachi H., Katsuno M., Sobue G., Taylor J.P., Sumner C.J., Fischbeck K.H., Pennuto M. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009, 63:316-328.
92. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
93. Parboosingh J.S., Figlewicz D.A., Krizus A., Meininger V., Azad N.A., Newman D.S., Rouleau G.A. Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. Neurology 1997, 49:568-572.
94. Parodi S., Pennuto M. Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Frontiers in Neuroendocrinology 2011, 32:416-425.
95. Peters M.F., Nucifora F.C., Kushi J., Seaman H.C., Cooper J.K., Herring W.J., Dawson V.L., Dawson T.M., Ross C.A. Nuclear targeting of mutant Huntingtin increases toxicity. Molecular and Cellular Neurosciences 1999, 14:121-128.
96. Piccioni F., Pinton P., Simeoni S., Pozzi P., Fascio U., Vismara G., Martini L., Rizzuto R., Poletti A. Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motor neuronal processes. FASEB Journal 2002, 16:1418-1420.
97. Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Frontiers in Neuroendocrinology 2004, 25:1-26.
98. Puls I., Jonnakuty C., LaMonte B.H., Holzbaur E.L., Tokito M., Mann E., Floeter M.K., Bidus K., Drayna D., Oh S.J., Brown R.H., Ludlow C.L., Fischbeck K.H. Mutant dynactin in motor neuron disease. Nature Genetics 2003, 33:455-456.
99. Ranganathan S., Harmison G.G., Meyertholen K., Pennuto M., Burnett B.G., Fischbeck K.H. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Human Molecular Genetics 2009, 18:27-42.
100. Ranganathan S., Fischbeck K.H. Therapeutic approaches to spinal and bulbar muscular atrophy. Trends in Pharmacological Sciences 2010, 31:523-527.
101. Rhodes L.E., Freeman B.K., Auh S., Kokkinis A.D., La Pean A., Chen C., Lehky T.J., Shrader J.A., Levy E.W., Harris-Love M., Di Prospero N.A., Fischbeck K.H. Clinical features of spinal and bulbar muscular atrophy. Brain 2009, 132:3242-3251.
102. Rocchi C., Greco V., Urbani A., Di Giorgio A., Priori M., Massa R., Bernardi G., Marfia G.A. Subclinical autonomic dysfunction in spinobulbar muscular atrophy (Kennedy disease). Muscle and Nerve 2011, 44:737-740.
103. Ross C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35:819-822.
104. Rusmini P., Simonini F., Crippa V., Bolzoni E., Onesto E., Cagnin M., Sau D., Ferri N., Poletti A. 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiology of Disease 2011, 41:83-95.
105. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
106. Schmidt B.J., Greenberg C.R., Allingham-Hawkins D.J., Spriggs E.L. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002, 59:770-772.
107. Simeoni S., Mancini M.A., Stenoien D.L., Marcelli M., Weigel N.L., Zanisi M., Martini L., Poletti A. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Human Molecular Genetics 2000, 9:133-144.
108. Sinclair R., Greenland K.J., Egmond S., Hoedemaker C., Chapman A., Zajac J.D. Men with Kennedy disease have a reduced risk of androgenetic alopecia. British Journal of Dermatology 2007, 157:290-294.
109. Sobue G., Hashizume Y., Mukai E., Hirayama M., Mitsuma T., Takahashi A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989, 112(Pt 1):209-232.
110. Sobue G., Hashizume Y., Yasuda T., Mukai E., Kumagai T., Mitsuma T., Trojanowski J.Q. Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells. Acta Neuropathologica 1990, 79:402-408.
111. Sobue G., Doyu M., Kachi T., Yasuda T., Mukai E., Kumagai T., Mitsuma T. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. Journal of the Neurological Sciences 1993, 117:74-78.
112. Sopher B.L., Thomas P.S., LaFevre-Bernt M.A., Holm I.E., Wilke S.A., Ware C.B., Jin L.W., Libby R.T., Ellerby L.M., La Spada A.R. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 2004, 41:687-699.
113. Soraru G., D'Ascenzo C., Polo A., Palmieri A., Baggio L., Vergani L., Gellera C., Moretto G., Pegoraro E., Angelini C. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. Journal of the Neurological Sciences 2008, 264:100-105.
114. Sperfeld A.D., Karitzky J., Brummer D., Schreiber H., Haussler J., Ludolph A.C., Hanemann C.O. X-linked bulbospinal neuronopathy: Kennedy disease. Archives of Neurology 2002, 59:1921-1926.
115. Sperfeld A.D., Hanemann C.O., Ludolph A.C., Kassubek J. Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology 2005, 64:753-754.
116. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housman D.E., Jackson G.R., Marsh J.L., Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
117. Suzuki E., Zhao Y., Ito S., Sawatsubashi S., Murata T., Furutani T., Shirode Y., Yamagata K., Tanabe M., Kimura S., Ueda T., Fujiyama S., Lim J., Matsukawa H., Kouzmenko A.P., Aigaki T., Tabata T., Takeyama K., Kato S. Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:3818-3822.
118. Suzuki K., Katsuno M., Banno H., Takeuchi Y., Atsuta N., Ito M., Watanabe H., Yamashita F., Hori N., Nakamura T., Hirayama M., Tanaka F., Sobue G. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008, 131:229-239.
119. Suzuki K., Katsuno M., Banno H., Takeuchi Y., Kawashima M., Suga N., Hashizume A., Hama T., Uchida K., Yamashita F., Nakamura T., Hirayama M., Tanaka F., Sobue G. The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy. Journal of Neurology, Neurosurgery and Psychiatry 2010, 81:567-571.
120. Szebenyi G., Morfini G.A., Babcock A., Gould M., Selkoe K., Stenoien D.L., Young M., Faber P.W., MacDonald M.E., McPhaul M.J., Brady S.T. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 2003, 40:41-52.
121. Takeyama K., Ito S., Yamamoto A., Tanimoto H., Furutani T., Kanuka H., Miura M., Tabata T., Kato S. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002, 35:855-864.
122. Tanaka F., Doyu M., Ito Y., Matsumoto M., Mitsuma T., Abe K., Aoki M., Itoyama Y., Fischbeck K.H., Sobue G. Founder effect in spinal and bulbar muscular atrophy (SBMA). Human Molecular Genetics 1996, 5:1253-1257.
123. Tanaka F., Reeves M.F., Ito Y., Matsumoto M., Li M., Miwa S., Inukai A., Yamamoto M., Doyu M., Yoshida M., Hashizume Y., Terao S., Mitsuma T., Sobue G. Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor--gene expression level. American Journal of Human Genetics 1999, 65:966-973.
124. Taylor J.P., Tanaka F., Robitschek J., Sandoval C.M., Taye A., Markovic-Plese S., Fischbeck K.H. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Human Molecular Genetics 2003, 12:749-757.
125. Thomas M., Dadgar N., Aphale A., Harrell J.M., Kunkel R., Pratt W.B., Lieberman A.P. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. Journal of Biological Chemistry 2004, 279:8389-8395.
126. Tokui K., Adachi H., Waza M., Katsuno M., Minamiyama M., Doi H., Tanaka K., Hamazaki J., Murata S., Tanaka F., Sobue G. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Human Molecular Genetics 2009, 18:898-910.
127. Udd B., Juvonen V., Hakamies L., Nieminen A., Wallgren-Pettersson C., Cederquist K., Savontaus M.L. High prevalence of Kennedy's disease in Western Finland - is the syndrome underdiagnosed?. Acta Neurologica Scandinavica 1998, 98:128-133.
128. Unrath A., Muller H.P., Riecker A., Ludolph A.C., Sperfeld A.D., Kassubek J. Whole brain-based analysis of regional white matter tract alterations in rare motor neuron diseases by diffusion tensor imaging. Human Brain Mapping 2010, 31:1727-1740.
129. Verhovshek T., Cai Y., Osborne M.C., Sengelaub D.R. Androgen regulates brain-derived neurotrophic factor in spinal motoneurons and their target musculature. Endocrinology 2010, 151:253-261.
130. Waza M., Adachi H., Katsuno M., Minamiyama M., Sang C., Tanaka F., Inukai A., Doyu M., Sobue G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nature Medicine 2005, 11:1088-1095.
131. Wyttenbach A. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis. Journal of Molecular Neuroscience 2004, 23:69-96.
132. Yamada M., Inaba A., Shiojiri T. X-linked spinal and bulbar muscular atrophy with myasthenic symptoms. Journal of the Neurological Sciences 1997, 146:183-185.
133. Yang Z., Chang Y.J., Yu I.C., Yeh S., Wu C.C., Miyamoto H., Merry D.E., Sobue G., Chen L.M., Chang S.S., Chang C. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nature Medicine 2007, 13:348-353.
134. Young J.E., Garden G.A., Martinez R.A., Tanaka F., Sandoval C.M., Smith A.C., Sopher B.L., Lin A., Fischbeck K.H., Ellerby L.M., Morrison R.S., Taylor J.P., La Spada A.R. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. Journal of Neuroscience 2009, 29:1987-1997.
135. Yu Z., Dadgar N., Albertelli M., Gruis K., Jordan C., Robins D.M., Lieberman A.P. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. Journal of Clinical Investigation 2006, 116:2663-2672.
136. Yu Z., Wang A.M., Robins D.M., Lieberman A.P. Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice. Disease Models & Mechanisms 2009, 2:500-507.
137. Yu Z., Wang A.M., Adachi H., Katsuno M., Sobue G., Yue Z., Robins D.M., Lieberman A.P. Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. PLoS Genetics 2011, 7:e1002321.